SCHEMBL5543465

SCHEMBL5543465

COc1ccc(CCNC(=O)C(C)(C)C(C)C)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA9 Q16790 1/20 0.61
MAPT P10636 1/20 0.58
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 1/20 0.56
MEN1 O00255 2/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10223234 0.86 CA12 (0.68) CA12CA1CA2CA9MAPT
SCHEMBL2745785 0.84 CA12 (0.64) CA12CA1CA2CA9MAPT
SCHEMBL10266158 0.82 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2KMT2ALMNAGAA
SCHEMBL1968355 0.82 CA12 (0.66) CA12CA1CA2CA9MAPT
SCHEMBL22126639 0.82 CA12 (0.53) CA12CA1CA2CA9MAPT
SCHEMBL903446 0.81 CA12 (0.64) CA12CA1CA2CA9MAPT
SCHEMBL16115911 0.81 CA12 (0.64) CA12CA1CA2CA9MAPT
SCHEMBL31432851 0.81 CA12 (0.64) CA12CA1CA2CA9MAPT
SCHEMBL5540930 0.81 MTNR1A (0.54) ALDH1A1SMN1; SMN2KMT2ALMNAMEN1
SCHEMBL3345207 0.81 CA12 (0.68) CA12CA1CA2CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367666-B2 3-carbamoyl-2-pyridone derivatives SHIONOGI & CO., LTD. (JP) 2013-02-05 US disclosed
US-8178681-B2 methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency SHIONOGI & CO., LTD. (JP) 2012-05-15 US disclosed